title: [Effect of tanshinone IIA pretreatment on IL-1β and RelA mRNA expression in rats with focal cerebral ischemia].
abstract: OBJECTIVE
  To observe the effect of tanshinone IIA (TS IIA) pretreatment on the expression of the inflammatory factor IL-1β and RelA mRNA in rats with focal cerebral ischemia.
  
  
  METHODS
  A total of 100 adult male SD rats were randomly divided into 6 groups, namely the model, ischemic preconditioning (IPC), TSIIA preconditioning, TSIIA treatment, sham-operated, and blank control groups. In the former 4 groups, rat models of focal cerebral ischemia were established with corresponding treatments. The expressions of IL-1β and RelA mRNA in each group were detected using RT-PCR.
  
  
  RESULTS
  All the groups showed expressions of IL-1β and RelA mRNA with the exception of the blank control group. Compared to the model group, TSIIA preconditioning group, TSIIA treatment group, and IPC group all had significantly reduced expression of IL-1β and RelA mRNA (P < 0.05). The expressions were lower in IPC group than in TSIIA preconditioning group and TSIIA treatment group(P < 0.05), and no significant difference was found in the expressions between the latter two groups.
  
  
  CONCLUSIONS
  The protective effect of pretreatment with TS IIA against cerebral ischemia is related to the reduction of IL-1β and RelA mRNA expressions.
authors.affiliation: Department of nurology, Affiliated Hospital, ChengDu University of TCM, ChengDu University of TCM, Chendu 610072, China. weiyinchen 2000@yahoo.com.cn
authors.forename: Wei-yin
authors.initials: WY
authors.lastname: Chen
authors.forename: Cheng-ming
authors.initials: CM
authors.lastname: Sun
authors.forename: Hui-ming
authors.initials: HM
authors.lastname: Wang
authors.forename: Mei
authors.initials: M
authors.lastname: Huang
authors.forename: Guan-xiang
authors.initials: GX
authors.lastname: Zhu
authors.forename: Bi-de
authors.initials: BD
authors.lastname: Zhu
authors.forename: Fu-you
authors.initials: FY
authors.lastname: Liu
mesh_terms: D045784:Abietanes / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use*; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use; D002545:Brain Ischemia / Q000188:drug therapy* / Q000378:metabolism; D020244:Infarction, Middle Cerebral Artery / Q000188:drug therapy / Q000378:metabolism; D053583:Interleukin-1beta / Q000235:genetics / Q000378:metabolism*; D008297:Male; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D015427:Reperfusion Injury / Q000517:prevention & control*; D051996:Transcription Factor RelA / Q000235:genetics / Q000378:metabolism*
chemical_list: D045784:Abietanes; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000975:Antioxidants; D053583:Interleukin-1beta; D012333:RNA, Messenger; C498145:Rela protein, rat; D051996:Transcription Factor RelA; C021751:tanshinone